Recent NGEN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 08:35:19 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/26/2026 08:30:34 PM
- Form F-X - Appointment of Agent for Service of Process and Undertaking • Edgar (US Regulatory) • 05/26/2026 01:40:03 PM
- Form F-10 - Registration Statement for Securities of certain Canadian Issuers. • Edgar (US Regulatory) • 05/26/2026 01:26:25 PM
- NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study • GlobeNewswire Inc. • 05/26/2026 11:15:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 09:24:31 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/22/2026 09:20:13 PM
- NervGen Announces Pricing of US$60.0 Million Public Offering of Securities • GlobeNewswire Inc. • 05/22/2026 03:27:00 AM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 05/21/2026 08:34:51 PM
- NervGen Announces Proposed Public Offering of Securities • GlobeNewswire Inc. • 05/21/2026 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/18/2026 08:19:44 PM
- NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 05/18/2026 11:15:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 08:28:48 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/07/2026 08:06:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/27/2026 09:05:57 PM
- NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer • GlobeNewswire Inc. • 04/27/2026 11:30:00 AM
- NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference • GlobeNewswire Inc. • 04/13/2026 11:45:00 AM
- NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 03/31/2026 11:45:00 AM
- Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)] • Edgar (US Regulatory) • 03/31/2026 11:30:34 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/13/2026 09:04:36 PM
- NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange • GlobeNewswire Inc. • 03/12/2026 08:15:00 PM
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs • GlobeNewswire Inc. • 03/04/2026 12:30:00 PM
- NervGen Pharma to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/18/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2026 09:05:54 PM
